Pfizer Inc. (NYSE:PFE) Stock Holdings Increased by Cypress Wealth Services LLC

Cypress Wealth Services LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 6.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,725 shares of the biopharmaceutical company’s stock after buying an additional 1,059 shares during the quarter. Cypress Wealth Services LLC’s holdings in Pfizer were worth $449,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Mcdonald Partners LLC lifted its holdings in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after purchasing an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in Pfizer during the 4th quarter worth about $264,000. Harvey Capital Management Inc. purchased a new stake in Pfizer during the fourth quarter valued at about $544,000. ING Groep NV boosted its holdings in shares of Pfizer by 48.6% in the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company’s stock worth $26,881,000 after buying an additional 331,403 shares during the period. Finally, WCM Investment Management LLC raised its holdings in shares of Pfizer by 128.7% during the fourth quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company’s stock valued at $3,062,000 after acquiring an additional 65,238 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Trading Up 0.3%

Shares of NYSE:PFE opened at $23.42 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $133.15 billion, a P/E ratio of 16.61, a P/E/G ratio of 0.64 and a beta of 0.58. The stock’s 50-day moving average is $23.02 and its 200-day moving average is $25.02.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.